Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare genetic intellectual disability syndrome characterized by global developmental delay, intellectual disability, severe speech delay, behavioral abnormalities (including impulsivity, compulsivity, stubbornness, manipulative behaviors, temper tantrums, and aggressive behaviors), autism spectrum disorder and mild and variable dysmorphic facies (including deep-set eyes and a prominent nasal septum, extending below the alae nasi) due to point mutation of USP7 gene or 16p13.2 microdeletion where USP7 is completely or partially deleted. Behavioral abnormalities are more pronounced in microdeletion. Patients may also have hypotonia, feeding problems, delayed walking with unsteady gait, hypogonadism in males, seizures and ocular anomalies (such as myopia, estropia, strabismus, and nystagmus).
No HPO annotations are available for this condition.
USP7-related Hao-Fountain syndrome is characterized by developmental delay/ intellectual disability (mild to severe), hypotonia, and infantile feeding difficulties. Brain MRI anomalies, primarily affecting the white matter, are present in a majority of individuals. Contractures and genitourinary anomalies are present in a subset of affected individuals. However, none of these features are specific to USP7-related Hao-Fountain syndrome, and affected individuals exhibit broad variability. To date, more than 250 individuals have been identified with a pathogenic variant in USP7 [, , , ]. The following description of the phenotypic features associated with this condition is based on these reports. Table 2. Select Features of USP7-Related Hao-Fountain Syndrome
No consensus clinical diagnostic criteria for USP7-related Hao-Fountain syndrome have been published.
USP7-related Hao-Fountain syndrome should be considered in probands with the following clinical and brain MRI findings and family history.
Clinical findings
Mild-to-severe developmental delay or intellectual disability
No approved treatments are currently available for Hao-Fountain syndrome. The disease remains an area of unmet medical need.
No clinical practice guidelines for USP7-related Hao-Fountain syndrome have been published. In the absence of published guidelines, the following recommendations are based on the authors' personal experience managing individuals with this disorder.
To establish the extent of disease and needs in an individual diagnosed with USP7-related Hao-Fountain syndrome, the evaluations summarized (if not performed as part of the evaluation that led to diagnosis) are recommended.
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. Table 5. USP7-Related Hao-Fountain Syndrome: Recommended Surveillance
No clinical trials have been registered for Hao-Fountain syndrome.
16 publications have been identified in PubMed for Hao-Fountain syndrome. Research spans Basic Science / Preclinical (60%), Gene Therapy / Novel Therapeutics (20%), and Diagnostic / Biomarker (7%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 9 | 60% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 6:58 PM UTC
European rare disease database
Common questions about Hao-Fountain syndrome
Feature | % of Persons w/Feature | Comment |
|---|---|---|
Developmental delay | 100% | — |
Intellectual disability | 50% | Most of those w/full-scale IQ 85 show specific learning disabilities. |
Muscular hypotonia | 73%-79% | This may transition to high muscle tone in later life. |
Autism spectrum disorder | 72% | — |
Brain MRI anomalies | 68%-73% | White matter paucity, hypoplastic corpus callosum |
Abnormal/unsteady gait | 66% | — |
Feeding difficulties | 55% | — |
Dental issues | 55% | — |
Impaired bone mineralization | 54% | May lead to fractures |
Eye anomalies | 53%-65% | Strabismus, refractive errors, nystagmus |
Sleep disturbance | 47% | Sleep apnea is present in almost 1/3 of affected persons. |
Epilepsy | 40% | — |
Hyperphagia | 39% | Mild to moderate |
Macrocephaly | 35% | — |
GERD | 37%-50% | — |
Hypogonadism | 25%-44% (males) | Incl micropenis /or undescended testes in males |
Contractures | 24% | — |
Hearing loss | 15% | GERD = gastroesophageal reflux disease; IQ = intellectual quotient Developmental delay and intellectual disability are common among affected individuals. |
Source: GeneReviews — "USP7-Related Hao-Fountain Syndrome"
Source: GeneReviews — "USP7-Related Hao-Fountain Syndrome"
Because the phenotypic features associated with USP7-related Hao-Fountain syndrome are not sufficient to diagnose this condition, all disorders with intellectual disability without other distinctive findings should be considered in the differential diagnosis. See OMIM Phenotypic Series for genes associated with:
• Autosomal dominant intellectual developmental disorders
• Autosomal recessive intellectual developmental disorders
• Nonsyndromic X-linked intellectual developmental disorders
• Syndromic X-linked intellectual developmental disorders
Source: GeneReviews — "USP7-Related Hao-Fountain Syndrome"
Biomarker and diagnostic research for Hao-Fountain syndrome has been reported in the published literature.
Table 3.
USP7-Related Hao-Fountain Syndrome: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comment
Constitutional
| Measurement of growth parameters | • To assess for growth deficiency obesity
In those w/short stature, consider endocrine eval for growth hormone deficiency.
| • Neurologic eval
Assess for gait abnormalities in those who are ambulatory.
| • Consider brain MRI.
Consider EEG if seizures are a concern.
| Developmental assessment | • To incl motor, adaptive, cognitive, speech-language eval
Eval for early intervention/ special education
Neurobehavioral/
| Neuropsychiatric eval | For persons age 12 mos: screening for concerns incl sleep disturbances, ADHD, /or findings suggestive of ASD
Gastrointestinal/
| • Gastrointestinal eval
Eval of weight gain
| To assess for:
Prolonged neonatal jaundice in newborns
Aspiration risk signs of GERD
Constipation or obstipation
Signs of hyperphagia or excessive weight gain
Source: GeneReviews — "USP7-Related Hao-Fountain Syndrome"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "USP7-Related Hao-Fountain Syndrome"
View trials for Hao-Fountain syndrome
Evaluation |
|---|
Frequency |
|---|
Psychiatric | Assessment for anxiety, ADHD, ASD, aggression, self-injury | Annually Musculoskeletal |
Ophthalmologic involvement | Ophthalmology eval | Per ophthalmologist |
Respiratory | Monitor for evidence of aspiration, respiratory insufficiency, sleep disturbance (incl for signs/symptoms of sleep apnea). | At each visit |
Endocrine | Monitor for signs symptoms of puberty. | At each visit from ages 7 yrs to late teenage yrs Endocrinologic tests for adrenal insufficiency |
Hearing | Audiology eval | Annually in childhood or as clinically indicated |
Source: GeneReviews — "USP7-Related Hao-Fountain Syndrome"
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
3 |
20% |
Testing and diagnosis research | 1 | 7% |
Patient case studies | 1 | 7% |
Disease patterns and progression | 1 | 7% |
Zigler CK (2026). [PMID: 41114730](https://pubmed.ncbi.nlm.nih.gov/41114730/). *J Child Psychol Psychiatry*. [Epidemiology / Natural History]
van der Laan L (2026). [PMID: 41713382](https://pubmed.ncbi.nlm.nih.gov/41713382/). *Stem Cell Res*. [Basic Science / Preclinical]
Korchak EJ (2026). [PMID: 42094436](https://pubmed.ncbi.nlm.nih.gov/42094436/). *bioRxiv*. [Basic Science / Preclinical]
van der Laan L (2026). [PMID: 41799441](https://pubmed.ncbi.nlm.nih.gov/41799441/). *Front Cell Dev Biol*. [Basic Science / Preclinical]
Wolf van der Meer J (2025). [PMID: 39919828](https://pubmed.ncbi.nlm.nih.gov/39919828/). *Genes Dev*. [Basic Science / Preclinical]
Jaen Maisonet I (2025). [PMID: 41086218](https://pubmed.ncbi.nlm.nih.gov/41086218/). *Proc Natl Acad Sci U S A*. [Gene Therapy / Novel Therapeutics]
Valles GJ (2025). [PMID: 40397674](https://pubmed.ncbi.nlm.nih.gov/40397674/). *Proc Natl Acad Sci U S A*. [Basic Science / Preclinical]
Korchak EJ (2025). [PMID: 40982686](https://pubmed.ncbi.nlm.nih.gov/40982686/). *Proc Natl Acad Sci U S A*. [Basic Science / Preclinical]
Chen H (2025). [PMID: 39862434](https://pubmed.ncbi.nlm.nih.gov/39862434/). *Cell Rep*. [Basic Science / Preclinical]
Korchak EJ (2025). [PMID: 40166258](https://pubmed.ncbi.nlm.nih.gov/40166258/). *bioRxiv*. [Basic Science / Preclinical]